The Difference Between Access on Paper and Access in Practice
Understand why specialty drug access breaks down after coverage is approved and how employers can close the gap between coverage and care.
Understand why specialty drug access breaks down after coverage is approved and how employers can close the gap between coverage and care.
If you spend your days looking at pharmacy trend reports and renewal spreadsheets, it is easy to forget what those numbers really represent.
Human-led Care Guides reduce friction in complex medication moments, helping employees start and stay on therapy. The result: better experience, higher confidence, and stronger retention for employers.
Outcomes don’t improve by accident. Better processes, faster therapy access, and clear guidance are the foundation of patient-centered prescription care—and the new standard employers should expect.
Rebates don’t equal value. Here’s how to align to net cost, enable substitution, and keep your people on track.
If we had five minutes between meetings, here’s what I’d share: biosimilars are no longer a maybe. They’re a practical way to protect your budget and keep care steady for your people.
If you manage employer benefits, you’re staring at a 2026 puzzle: demand for GLP-1 medications keeps climbing while prices remain elevated, and oral options may expand utilization further.
Right now, there’s a storm brewing in specialty drug trend—and most plan sponsors don’t even see it coming. If you’re focused
They promise weight loss. But without a plan, GLP-1s can quietly become your biggest prescription care expense.
Offering health benefits to employees is a critical responsibility—and a complex one.